Regeneron Pharmaceuticals (REGN)
(Real Time Quote from BATS)
$1,059.99 USD
+4.42 (0.42%)
Updated Jul 24, 2024 03:55 PM ET
After-Market: $1,060.80 +0.81 (0.08%) 4:18 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Regeneron (REGN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$1,087.50 | $1,250.00 | $720.00 | 3.02% |
Price Target
Based on short-term price targets offered by 22 analysts, the average price target for Regeneron comes to $1,087.50. The forecasts range from a low of $720.00 to a high of $1,250.00. The average price target represents an increase of 3.02% from the last closing price of $1,055.57.
Analyst Price Targets (22)
Broker Rating
Regeneron currently has an average brokerage recommendation (ABR) of 1.54 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 26 brokerage firms. The current ABR compares to an ABR of 1.54 a month ago based on 26 recommendations.
Of the 26 recommendations deriving the current ABR, 19 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 73.08% and 3.85% of all recommendations. A month ago, Strong Buy made up 73.08%, while Buy represented 3.85%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 19 | 19 | 19 | 19 | 18 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 5 | 5 | 5 | 5 | 5 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.54 | 1.54 | 1.54 | 1.54 | 1.56 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/22/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Hold | Hold |
7/18/2024 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
7/12/2024 | UBS | Colin N Bristow | Strong Buy | Strong Buy |
7/10/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/9/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
6/27/2024 | Canaccord Genuity | John L Newman | Strong Buy | Strong Buy |
6/25/2024 | Argus Research Corp. | Jasper Hellweg | Strong Buy | Strong Buy |
5/20/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/13/2024 | Evercore Partners | Cory Kasimov | Not Available | Strong Buy |
5/3/2024 | SVB Securities | David Risinger | Strong Buy | Strong Buy |
4/25/2024 | Wells Fargo Securities | Mohit Bansal | Strong Buy | Strong Buy |
4/22/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Tyler Van Buren | Strong Buy | Strong Buy |
3/31/2024 | Goldman Sachs | Salveen Richter | Strong Buy | Strong Buy |
3/11/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
3/1/2024 | Not Identified | Not Identified | Not Available | Hold |
2/5/2024 | Robert W. Baird & Co. | Brian P Skorney | Hold | Hold |
2/5/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
12/11/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
9/15/2023 | WestPark Capital | Karen Sterling | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.54 |
ABR (Last week) | 1.54 |
# of Recs in ABR | 26 |
Average Target Price | $1,087.50 |
LT Growth Rate | 13.00% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 85 of 252 |
Current Quarter EPS Est: | 10.49 |